John LaMattina takes on Marcia Angell and her recent interview. It sounds like he made it farther into the podcast than I could: âThe drug companies do almost no innovation nowadaysâ¦.. All they have to do is the late development. And thatâs the clinical trials. Now that is an expensive part of the process. But it is not an innovative part of the process.â . . .innovation doesnât only...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to LaMattina on Angell
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account